ABOS
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc
$ABOS reports Q1 2023 financial results and provides updates on its Alzheimer's therapeutics development
Acumen Pharmaceuticals reported a net loss of $11.9 million in Q1 2023, along with an increase in overall expenses resulting from ongoing clinical trials, nonclinical R&D activity, personnel, consulting, and travel costs. However, the biopharmaceutical company anticipates reporting topline results and a favorable interaction with the FDA regarding ACU193, a treatment for early AD, during Q3 and Q4 2023, respectively. Acumen also revealed a cash balance of $193.4 million as of December 31, 2022, and plans to present clinical evidence regarding ACU193's pharmacokinetic profile, safety, and engagement targets, including potential monthly dosing.
4mo ago
$ABOSAcumen Pharmaceuticals Inc
$ABOS reports Acumen Pharma's $193M cash balance and ACU193 drug update.
Acumen Pharmaceuticals releases 2022 financial results, shows cash balance of $193.4m as of Dec. 31, 2022, and provides a business update, including ACU193, a drug for treating Alzheimer's disease. Phase 1 topline results are expected to report in Q3 2023, while FDA interaction may happen in Q4 2023. ACU193 was granted Fast Track designation in Oct. 2022. The company also expanded its team, appointing Liean Schenck as VP of Chemistry and Manufacturing and Derek Meisner as Chief Legal Officer. Despite reporting a net loss of $42.1m for 2021, the company is optimistic about ACU193.
6mo ago
$ABOS